Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia

Cytokines and Molecular Therapy

Volumn 2, Issue 2, 1996, Pages 215-223

  Raghavachar, Aruna ^a,b   Ganser, Arnold ^c,d   Freund, Mathias ^e   Heimpel, Hermann ^a   Herrmann, Friedhelm ^f   Schrezenmeier, Hubert ^f  

^a UNIVERSITY OF ULM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Aplastic anemia; Immunosuppression; Interleukin 3; Treatment

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT INTERLEUKIN 3; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HISTIOCYTOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JOINT STIFFNESS; LYMPHOPROLIFERATIVE DISEASE; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; COLONY-FORMING UNITS ASSAY; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-3; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PATIENT SELECTION; PLATELET COUNT; RECOMBINANT PROTEINS; RETICULOCYTE COUNT; TIME FACTORS;

EID: 0030502943     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Frickhofen N, Schrezenmeier H, Bacigalupo N, Results of European trials of immunosuppression for treatment of aplastic anemia. In: Ontogeny of liematopoiesis -Aplastic anemia (ed E Gluckman, L Coulombel) 335-43. Editions John Libbey Eurotext, Montrouge/London, 1995.
2. Rosenfeld SJ, Kimball J, Vining D, Young NS, Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood (1995) 85: 3058-65.
3. Frickhofen N, Kaltwasser JP, Schrezenmeier H et al, Treatment of aplastic enemia with antilymphocyte globulin and methylprednisolone with or without cyclosporin. N EnglJMed (1991) 324: 1297-304.
4. Tichelli A, Gratwohl A, Nissen C et al, Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood (1992) 80: 337-45.
5. Ganser A, Therapeutic use of hemopoietic growth factors in patients with aplastic anemia. In: Aplastic Anemia -Current perspectives on the patliogenesis and treatment (ed A Raghavachar, H Schrezenmeier, N Frickhofen) 110-7. Blackwell-MZV, Vienna, 1993.
6. Gratwohl A, Hematopoietic growth factors in the treatment of aplastic anemia. Emphasis on European studies. In: Ontogeny of liematopoiesis -Aplastic anemia (ed E Gluckman, L Coulombel) 345-53. Editions John Libbey Eurotext, Montrouge/London, 1995.
7. Nimer SD, Paquette RL, Ireland P et al, A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol (1994) 22: 875-80.
8. Kurzrock R, Talpaz M, Estrov Z et al, Phase I study of recombinant human interleukin-3 in patients with bone marrow faüure. J Clin Oiicol (1991) 9: 1241-50.
9. Ganser A, Lindemann A, Scipelt G et al, Effects of recombinant human interleukin-3 in aplastic anemia. Blood (1990) 16: 1287-92.
10. Bargetzi MJ, Gluckman E, Tichelli A et al, Recombinant human interleukin-3 in refractory severe aplastic anaemia: a phase I/II trial. Br J Haematol (1995) 91: 306-12.
11. Gillio AP, Castro Malaspina H, Gasparetto C et al, Human recombinant interleukin-3 treatment in patients with myelodysplastic syndrome and aplastic anemia (abst). Stood (1995) 78(Suppl 1): 95a.
12. Bacigalupo A, Broccia G, Corda G et al, Anülymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic .anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood (1995) 85: 1348-53.
13. International Agranulocytosis and Aplastic Anemia Study, Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood (1987) 70: 1718-21.
14. Gillis G, Urdal DL, Clergenger W et al, Production of recombinant human colony stimulating factors in yeast. Behring Inst Mitt (1988) 83: 1-7.
15. Schrezenmeier H, Thome SD, Tewald F et al, Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. Exp Hematol (1993) 21: 358-65.
16. Schrezenmeier H, Marsh JCW, Stromeyer P et al, A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia. Brjf Haematol (1995) 90:283-92.
17. Herrmann F, Lindemann A, Lange W et al, Medullary histiocytosis following treatment of severe aplastic anemia with recombinant human interleukin3 in combination with antilymphocyte globulin, cyclosporin A, and methylprednisolone. Ann Hematol (1991) 63:229-31.
18. Schrezenmeier H, Noe G, Raghavachar A et al, Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. Br J Haematol (1994) 88: 286-94.
19. Schrezenmeier H, Raghavachar A, Heimpel H, Granulocyte-macrophage colony-stimulating factor in the sera of patients with aplastic anemia. Clin Invest (1993) 71: 102-8.
20. Watari K, Asano S, Shirafuji N et al, Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood (1989) 73: 117-22.
21. Kojima S, Matsuyama T, Kodera Y et al, Measurement of endogenous plasma granulocyte colony-stimulating factor in patients with acquired aplastic anemia by a sensitive chemiluminescent immunoassay. Blood (1996) 87: 1303-8.
22. Nimer SD, Leung DH, Wolin MJ, Golde DW, Serum stem cell factor levels in patients with aplastic anemia. Int J Hematol (1994) 60: 185-9.
23. Wodnar Filipowicz A, Yancik' S, Moser Y et al, Levels of soluble stem cell factor in serum of patients with aplastic anemia. Blood (1993) 81: 3259-64.
24. Kojima S, Matsuyama T, Kodera Y, Hematopoietic growth factors released by marrow stromal cells from patients with aplastic anemia. Blood (1992) 79: 2256-61.
25. Cannistra SA, Vellenga E, Groshek P et al, Human granulocyte-monocyte colony stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood (1988) 71: 672-8.
26. Hirayama Y, Kongo Y, Matsunaga T et al, Cytokine mRNA expression of bone marrow stromal cells from patients with aplastic anaemia and myelodysplastic syndrome. BrJHaematol (1993) 85: 676-83.
27. Kawano Y, Nissen C, Gratwohl A, Speck B, Immunostimulatory effects of different antilymphocyte globulin preparations: a possible clue to their clinical effect. Br J Haematol (1988) 68: 115-9.
28. Taniguchi Y, Frickhofen N, Raghavachar A et al, Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and .release lymphokines. Enr J Haematol (1990) 44: 244-51.
29. Tong J, Bacigalupo A, Piaggio G et al, In vitro response of T cells from aplastic anemia patients to antilymphocyte globulin and phytohemagglutinin: colony-stimulating activity and lymphokine production. Exp Hematol (1991) 19: 312-6.
30. Barbano GC, Schenone A, Roncella S et al, Antilymphocyte globulin stimulates normal human T cells to proliferate and to release lymphokines in vitro. A study at the clonal level. Blood (1988) 72: 956-63.
31. Nimer SD, Golde DW, Kwan K et al, In vitro production of granulocyte-macrophage colonystimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin. Blood (1991) 78: 163-8.
32. Geissler K, Forstinger C, Kalhs P et al, Effect of interleukin-3 on responsiveness to granulocytecolony-stimulating factor in severe aplastic anemia. Ann Intern Med (1992) 117: 223-5.
33. Herrmann F, Lindemann A, Raghavachar A et al, In vivo recruitment of GM-CSF-response myelopoietic progenitor cells by interleukin-3 in aplastic anemia. Leukemia (1990) 4: 671-2.
34. Torok Storb B, Doney K, Brown SL, Prentice RL, Correlation of two in vitro tests with clinical response to immunosuppressive therapy in 54 patients with severe aplastic anemia. Blood (1984) 63: 349-55.
35. Nachbaur D, Gratwohl A, Herold M et al, Cytokine serum levels during treatment with high-dose recombinant human IL-3 in a patient with severe aplastic anemia. Ann Hematol (1993) 66: 71-5.
36. Sullivan JL, Epstein-Barr virus and lymphoproliferative disorders. Semin Hematol (1988) 25: 269-79.
37. Paul CG, Baumann MA, Modulation of spontaneous outgrowth of Epstein-Barr virus immortalized B-cell clones by granulocyte-macrophage colony stimulating factor and interIeukin-3. Blood (1990) 75: 54-8.
38. Socie G, Henry Amar M, Bacigalupo A et al, Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation -Severe Aplastic Anaemia Working Party. NEnglJMed (1993) 329: 1152-7.
39. Kojima S, Tsuchida M, Matsuyama T, Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF (letter). N EnglJ Aied (1992) 326: 1294-5.
40. Ohara A, Kojima S, Tsuchida M et al, Evolution of acquired severe aplastic anemia to MDS/leukemia in childhood: a retrospective study on 170 severe aplastic anemia child patients (abst). Blood (1995) 86(Suppl 1): 336a.
41. Schrezenmeier H, Hinterberger W, Hows J et al, Second immunosuppressive treatment of patients with aplastic anemia not responding to the first course of immunosuppression (IS): a report from the Working Party on Severe Aplastic Anemia of the EBMT (abst). Bone Marrow Transplant (1995) 15(Suppl 2): 10.